Blog
RSS FeedPosted by Michael Wonder on 22 Nov 2019
The life improvement value: a new measure of cost-efficiency
23 November 2019 - The decision not to make zoster vaccination available to people older than 79 years1 was based on ...
Posted by Michael Wonder on 27 Jul 2019
A non-inferiority framework for cost-effectiveness analysis
24 July 2019 - Traditional decision rules have limitations when a new technology is less effective and less costly than a ...
Posted by Michael Wonder on 01 May 2019
Drug maker Takeda to introduce value-based pricing in Europe
29 April 2019 - Japanese company to refund Crohn's disease patients with no improvements. ...
Posted by Michael Wonder on 05 Mar 2019
Future unrelated medical costs need to be considered in cost effectiveness analysis
5 March 2019 - New medical technologies that prolong life result in additional health care use in life years gained. Some ...
Posted by Michael Wonder on 27 Feb 2019
Economic analysis falls short when it comes to medicines’ value
26 February 2019 - For the past two decades, a plethora of organisations identified by various innocuous acronyms (e.g., NICE) ...
Posted by Michael Wonder on 21 Feb 2019
Linking cancer drug prices to treatment success could speed up approvals. But what do patients consider success?
21 February 2019 - The NHS spends more than £2 billion on cancer drugs each year in the UK. And ...
Posted by Michael Wonder on 14 Feb 2019
Determining value in health technology assessment: stay the course or tack away?
15 February 2019 - The economic evaluation of new health technologies to assess whether the value of the expected health benefits ...
Posted by Michael Wonder on 23 Jan 2019
Discrete choice experiments in health economics: past, present and future
23 January 2019 - Discrete choice experiments are increasingly advocated as a way to quantify preferences for health. ...
Posted by Michael Wonder on 20 Oct 2018
Cost, context, and decisions in health economics and health technology assessment
18 October 2018 - This study is an attempt to demystify and clarify the idea of cost in health economics ...
Posted by Michael Wonder on 27 Sep 2018
With payers under pressure, biosimilars must demonstrate their value
27 September 2018 - In recent years, payers in Europe have been increasing their scrutiny of new therapies as increasingly high-cost ...
Posted by Michael Wonder on 10 Aug 2018
Biosimilars for insulin: a cost-saving alternative?
11 August 2018 - The expiry of patents on an insulin analogue has opened the market to the production of biosimilar ...
Posted by Michael Wonder on 23 Apr 2018
Cost-effectiveness thresholds: the past, the present and the future
23 April 2018 - Cost-effectiveness (CE) thresholds are being discussed more frequently and there have been many new developments in this ...
Posted by Michael Wonder on 13 Apr 2018
Decision components of NICE's technology appraisals assessment framework
10 April 2018 - The UK's NICE is an established health technology assessment agency. de Folter et al. present a ...
Posted by Michael Wonder on 22 Mar 2018
Resolving the “cost-effective but unaffordable” paradox: estimating the health opportunity costs of non-marginal budget impacts
22 March 2018 - Considering whether or not a proposed investment (an intervention, technology, or program of care) is affordable is ...
Posted by Michael Wonder on 20 Feb 2018
Beyond QALYs: multi-criteria based estimation of maximum willingness to pay for health technologies
20 February 2018 - The QALY is a useful outcome measure in cost-effectiveness analysis. But in determining the overall value of ...